Recursion Pharmaceuticals, Inc. RXRX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s common stock, shares authorized (in shares)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported common stock, shares authorized (in shares) of $2B in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s common stock, shares authorized (in shares) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $2B to $2B.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s common stock, shares authorized (in shares) has grown at a 60.4% compound annual growth rate (CAGR), from $188.4M to $2B.